Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride

Journal of Analytical Science and Technology

Table 5 Data for water vapor transmission studies on the formulated transdermal patches

Formulation code	Initial wt. (g)	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7	Water vapor transmitted^a (g)	WVT rate (mg cm/cm² 24 h)^b
A1	51.81	52.03	52.16	52.25	52.38	52.55	52.83	52.99	1.18	0.0016
A2	51.26	51.38	51.48	51.57	51.69	51.76	51.89	51.97	0.71	0.0009
A3	51.54	51.66	51.78	51.91	52.08	52.23	52.32	52.45	0.91	0.0011
A4	51.34	51.43	51.48	51.57	51.68	51.76	51.85	51.97	0.63	0.0007
B1	51.7	51.86	52.04	52.17	52.29	52.44	52.51	52.64	0.94	0.0013
B2	51.56	51.62	51.71	51.8	51.91	52.01	52.18	52.29	0.73	0.0009
B3	51.45	51.58	51.73	51.86	52	52.07	52.19	52.29	0.84	0.0010
B4	51.31	51.36	51.48	51.67	51.8	51.89	51.97	52.06	0.75	0.0009
C1	51.82	51.98	52.15	52.29	52.49	52.51	52.69	52.88	1.06	0.0013
C2	51.77	51.88	52.01	52.14	52.29	52.41	52.48	52.57	0.8	0.0011
C3	51.57	51.69	51.87	52.04	52.17	52.34	52.44	52.54	0.97	0.0013
C4	51.75	51.83	51.94	52.07	52.19	52.29	52.38	52.46	0.71	0.0009

^aCalculated as final weight − initial weight of the patch
^bCalculated as (weight gained (mg) × thickness of the patch (mm)/surface area of patch (cm²)